10x Genomics (TXG) Financials

$21.52 +0.45 (+2.14%)

Closing price 04:00 PM Eastern

Extended Trading

$21.52 0.00 (0.00%)

As of 06:13 PM Eastern

Annual Income Statements for 10x Genomics

This table shows 10x Genomics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-19	-112	-31	-543	-58	-166	-255	-183	-44
Consolidated Net Income / (Loss)	-19	-112	-31	-543	-58	-166	-255	-183	-44
Net Income / (Loss) Continuing Operations	-19	-112	-31	-543	-58	-166	-255	-183	-44
Total Pre-Tax Income	-19	-112	-31	-534	-54	-162	-249	-178	-40
Total Operating Income	-18	-111	-31	-534	-52	-168	-265	-195	-61
Total Gross Profit	61	118	185	240	416	396	409	414	444
Total Revenue	71	146	246	299	490	516	619	611	643
Operating Revenue	71	146	246	299	490	516	619	611	643
Total Cost of Revenue	11	29	61	58	74	120	209	196	199
Operating Cost of Revenue	11	29	61	58	74	120	209	196	199
Total Operating Expenses	79	228	215	775	469	564	675	609	505
Selling, General & Admin Expense	47	88	131	202	258	298	343	344	316
Research & Development Expense	32	110	83	571	212	266	331	265	239
Other Operating Expenses / (Income)	-	-	-	-	-	-	0.00	0.00	-50
Total Other Income / (Expense), net	-0.37	-1.63	-0.46	1.19	-1.46	5.97	17	17	21
Interest Expense	0.81	2.41	3.08	1.68	0.87	-	0.03	0.00	0.00
Interest & Investment Income	0.31	1.02	2.81	1.53	0.21	6.65	17	19	20
Other Income / (Expense), net	0.14	-0.25	-0.19	1.34	-0.80	-0.20	-0.29	-2.07	1.03
Income Tax Expense	0.02	0.09	0.22	8.26	4.51	4.03	6.34	4.93	3.64
Basic Earnings per Share	($1.62)	($8.40)	($0.80)	($5.37)	($0.53)	($1.46)	($2.18)	($1.52)	($0.35)
Weighted Average Basic Shares Outstanding	11.59M	13.39M	39.09M	101.15M	110.35M	113.86M	117.17M	120.45M	124.75M
Diluted Earnings per Share	($1.62)	($8.40)	($0.80)	($5.37)	($0.53)	($1.46)	($2.18)	($1.52)	($0.35)
Weighted Average Diluted Shares Outstanding	11.59M	13.39M	39.09M	101.15M	110.35M	113.86M	117.17M	120.45M	124.75M
Weighted Average Basic & Diluted Shares Outstanding	11.59M	13.39M	39.09M	101.15M	112.84M	115.36M	119.17M	122.30M	127.75M

This table shows 10x Genomics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-93	-49	-60	-38	-36	-49	-34	35	-27	-16	-13
Consolidated Net Income / (Loss)	-93	-49	-60	-38	-36	-49	-34	35	-27	-16	-13
Net Income / (Loss) Continuing Operations	-93	-49	-60	-38	-36	-49	-34	35	-27	-16	-13
Total Pre-Tax Income	-92	-47	-58	-37	-34	-48	-34	37	-28	-15	-13
Total Operating Income	-95	-55	-61	-42	-41	-50	-39	30	-32	-20	-17
Total Gross Profit	96	116	93	104	106	111	105	125	100	113	106
Total Revenue	154	184	141	153	152	165	155	173	149	166	151
Operating Revenue	154	184	141	153	152	165	155	173	149	166	151
Total Cost of Revenue	58	68	48	49	45	54	49	48	49	53	45
Operating Cost of Revenue	58	68	48	49	45	54	49	48	49	53	45
Total Operating Expenses	190	171	154	146	148	161	145	95	133	133	123
Selling, General & Admin Expense	82	86	86	83	82	94	90	74	75	77	66
Research & Development Expense	108	85	69	63	66	67	64	61	57	56	57
Other Operating Expenses / (Income)	-	-	0.00	0.00	0.00	-	-9.20	-41	0.00	-	0.00
Total Other Income / (Expense), net	3.05	8.59	3.70	4.66	7.05	1.46	5.82	6.87	4.04	4.35	4.20
Interest & Investment Income	4.30	4.64	4.74	4.72	4.97	4.03	3.69	4.27	5.20	6.89	5.01
Other Income / (Expense), net	-1.25	3.96	-1.04	-0.06	2.08	-2.57	2.14	2.60	-1.17	-2.54	-0.82
Income Tax Expense	1.24	2.35	2.15	0.82	1.32	0.65	0.85	2.46	-0.73	1.06	0.62
Basic Earnings per Share	($0.79)	($0.42)	($0.50)	($0.32)	($0.30)	($0.40)	($0.28)	$0.28	($0.22)	($0.13)	($0.10)
Weighted Average Basic Shares Outstanding	117.73M	117.17M	119.39M	120.07M	120.73M	120.45M	122.61M	123.76M	125.50M	124.75M	128.29M
Diluted Earnings per Share	($0.79)	($0.42)	($0.50)	($0.32)	($0.30)	($0.40)	($0.28)	$0.28	($0.22)	($0.13)	($0.10)
Weighted Average Diluted Shares Outstanding	117.73M	117.17M	119.39M	120.07M	120.73M	120.45M	122.61M	124.51M	125.50M	124.75M	128.29M
Weighted Average Basic & Diluted Shares Outstanding	118.21M	119.17M	119.71M	120.49M	121.05M	122.30M	123.13M	124.49M	126.55M	127.75M	126.96M

This table details how cash moves in and out of 10x Genomics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	6.11	22	406	212	-93	-369	132	-15	130
Net Cash From Operating Activities	-11	-76	35	-218	-21	-34	-15	6.66	136
Net Cash From Continuing Operating Activities	-11	-76	35	-218	-21	-34	-15	6.66	136
Net Income / (Loss) Continuing Operations	-19	-112	-31	-543	-58	-166	-255	-183	-44
Consolidated Net Income / (Loss)	-19	-112	-31	-543	-58	-166	-255	-183	-44
Depreciation Expense	4.31	3.91	7.07	14	21	25	36	36	36
Amortization Expense	0.15	0.46	0.10	5.03	7.14	7.64	8.11	7.83	7.62
Non-Cash Adjustments To Reconcile Net Income	1.66	3.70	14	356	96	137	179	144	113
Changes in Operating Assets and Liabilities, net	1.95	28	45	-50	-87	-37	18	1.78	23
Net Cash From Investing Activities	-3.76	-6.71	-43	-38	-107	-351	133	-33	-13
Net Cash From Continuing Investing Activities	-3.76	-6.71	-43	-38	-107	-351	133	-33	-13
Purchase of Property, Plant & Equipment	-3.76	-6.28	-43	-37	-101	-132	-49	-12	-5.94
Acquisitions	0.00	-0.43	-0.03	-1.73	-5.45	-4.00	-0.92	-1.00	-9.27
Purchase of Investments	-	-	-	0.00	0.00	-283	0.00	-49	-123
Sale and/or Maturity of Investments	-	-	-	0.00	0.00	68	183	30	125
Net Cash From Financing Activities	21	105	415	469	35	16	14	11	6.80
Net Cash From Continuing Financing Activities	21	105	415	469	35	16	14	11	6.80
Repayment of Debt	0.00	-0.70	-11	-37	-5.03	-5.41	-5.81	0.00	0.00
Issuance of Common Equity	0.00	0.00	411	482	40	21	19	11	6.80
Effect of Exchange Rate Changes	-0.01	-0.02	-0.05	-0.46	0.23	-0.04	-0.03	-0.16	0.48
Cash Interest Paid	0.66	1.82	2.25	1.67	1.22	0.84	0.44	0.00	0.00
Cash Income Taxes Paid	0.00	0.01	0.02	0.28	8.66	3.93	4.93	5.64	2.39

This table details how cash moves in and out of 10x Genomics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-16	45	-3.50	24	18	-54	33	21	35	41	16
Net Cash From Operating Activities	-25	26	-16	7.50	22	-6.75	34	18	43	41	26
Net Cash From Continuing Operating Activities	-25	26	-16	7.50	22	-6.75	34	18	43	41	26
Net Income / (Loss) Continuing Operations	-93	-49	-60	-38	-36	-49	-34	35	-27	-16	-13
Consolidated Net Income / (Loss)	-93	-49	-60	-38	-36	-49	-34	35	-27	-16	-13
Depreciation Expense	9.37	9.72	9.19	8.97	8.96	8.75	8.02	7.82	10	10	9.96
Amortization Expense	2.05	1.99	2.30	1.93	1.79	1.81	1.79	1.84	1.95	2.04	1.95
Non-Cash Adjustments To Reconcile Net Income	40	46	39	38	34	33	31	28	27	27	23
Changes in Operating Assets and Liabilities, net	16	17	-5.85	-4.00	13	-1.42	28	-54	31	18	5.10
Net Cash From Investing Activities	4.90	13	11	12	-3.62	-52	-1.89	-0.94	-8.80	-1.81	-1.31
Net Cash From Continuing Investing Activities	4.90	13	11	12	-3.62	-52	-1.89	-0.94	-8.80	-1.81	-1.31
Purchase of Property, Plant & Equipment	-15	-3.45	-2.91	-2.88	-3.89	-2.72	-1.89	-1.58	-0.69	-1.78	-1.60
Purchase of Investments	-	-	-	-	-	-	0.00	-	-49	-25	-25
Sale and/or Maturity of Investments	20	17	14	16	0.27	-	0.00	50	50	25	25
Net Cash From Financing Activities	4.37	5.61	1.64	4.60	0.16	4.52	0.42	3.52	0.62	2.24	-8.42
Net Cash From Continuing Financing Activities	4.37	5.61	1.64	4.60	0.16	4.52	0.42	3.52	0.62	2.24	-8.42
Issuance of Common Equity	4.37	5.61	1.64	4.60	0.16	4.52	0.42	3.52	0.62	2.24	0.27
Other Financing Activities, net	-	-	-	-	-	-	0.00	-	-	-	-8.69
Effect of Exchange Rate Changes	-0.09	0.08	-0.05	-0.00	0.16	-0.27	0.11	0.36	-0.03	0.04	-0.07
Cash Income Taxes Paid	0.60	0.48	0.96	1.08	2.82	0.78	0.46	0.86	0.62	0.46	-0.28

This table presents 10x Genomics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	124	606	929	1,019	1,029	965	919	1,041
Total Current Assets	106	481	774	748	635	596	584	684
Cash & Equivalents	65	424	664	587	220	359	344	474
Short-Term Investments	-	-	-	0.00	210	29	49	49
Accounts Receivable	28	33	51	85	104	115	88	82
Inventories, net	8.57	15	30	60	82	74	83	56
Prepaid Expenses	4.50	8.03	13	14	17	19	19	22
Plant, Property, & Equipment, net	11	49	73	169	289	280	253	227
Total Noncurrent Assets	6.95	76	82	102	105	90	82	130
Goodwill	-	-	0.00	4.51	4.51	4.51	4.51	4.51
Intangible Assets	-	-	22	25	23	17	16	62
Other Noncurrent Operating Assets	6.95	76	60	72	77	68	61	63
Total Liabilities & Shareholders' Equity	124	606	929	1,019	1,029	965	919	1,041
Total Liabilities	101	186	190	201	223	224	209	245
Total Current Liabilities	32	63	118	110	131	127	118	153
Accounts Payable	8.79	13	4.71	17	22	16	13	13
Accrued Expenses	9.94	24	43	51	60	57	41	40
Current Deferred Revenue	2.40	3.30	4.47	5.34	7.87	13	21	24
Current Employee Benefit Liabilities	7.05	12	15	32	33	30	34	43
Other Current Liabilities	-	0.00	50	5.13	9.04	12	9.29	34
Total Noncurrent Liabilities	69	123	72	91	92	97	91	92
Noncurrent Deferred Revenue	4.43	16	-	-	3.17	8.81	13	11
Other Noncurrent Operating Liabilities	39	87	72	91	89	88	78	81
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-220	420	739	818	806	741	710	796
Total Preferred & Common Equity	-220	420	739	818	806	741	710	796
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-220	420	739	818	806	741	710	796
Common Stock	11	682	1,544	1,681	1,839	2,026	2,178	2,307
Retained Earnings	-231	-262	-805	-863	-1,029	-1,284	-1,467	-1,511
Accumulated Other Comprehensive Income / (Loss)	-0.04	-0.05	-0.05	0.02	-4.34	-0.43	-0.49	0.23

This table presents 10x Genomics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	996	1,014	990	949	923	930	938	903	980	1,027	1,016
Total Current Assets	629	602	583	562	567	579	594	580	656	660	670
Cash & Equivalents	234	332	326	311	356	380	398	377	398	433	490
Short-Term Investments	218	86	66	46	16	0.27	0.00	50	50	50	50
Accounts Receivable	84	78	88	104	91	91	84	53	119	97	56
Inventories, net	79	82	84	81	83	88	94	75	69	62	53
Prepaid Expenses	14	21	19	20	21	20	18	26	20	19	20
Plant, Property, & Equipment, net	258	292	285	285	269	263	259	246	240	233	221
Total Noncurrent Assets	109	120	122	101	86	87	85	78	85	135	125
Goodwill	4.51	4.51	4.51	4.51	4.51	4.51	4.51	4.51	4.51	4.51	4.51
Intangible Assets	23	23	22	22	16	17	16	15	15	65	60
Other Noncurrent Operating Assets	81	93	95	75	66	66	64	58	65	66	61
Total Liabilities & Shareholders' Equity	996	1,014	990	949	923	930	938	903	980	1,027	1,016
Total Liabilities	220	212	196	203	204	206	215	196	207	242	201
Total Current Liabilities	127	112	98	105	109	111	121	108	112	147	114
Accounts Payable	22	29	23	19	20	21	26	10	16	18	17
Accrued Expenses	62	47	34	36	42	42	38	45	39	36	34
Current Deferred Revenue	6.67	8.53	9.22	11	14	16	18	21	21	22	24
Current Employee Benefit Liabilities	28	18	22	28	21	20	30	22	26	37	22
Other Current Liabilities	8.39	9.20	9.29	10	11	11	9.42	9.44	9.67	34	17
Total Noncurrent Liabilities	94	100	98	99	95	95	94	89	94	95	88
Noncurrent Deferred Revenue	-	-	-	-	9.79	11	12	13	11	11	10
Other Noncurrent Operating Liabilities	94	100	98	99	86	83	81	76	83	83	78
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	776	802	793	745	719	724	723	707	773	785	814
Total Preferred & Common Equity	776	802	793	745	719	724	723	707	773	785	814
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	776	802	793	745	719	724	723	707	773	785	814
Common Stock	1,793	1,884	1,937	1,981	2,064	2,107	2,141	2,209	2,240	2,279	2,338
Retained Earnings	-1,012	-1,080	-1,142	-1,235	-1,344	-1,382	-1,418	-1,501	-1,467	-1,494	-1,524
Accumulated Other Comprehensive Income / (Loss)	-5.49	-1.48	-0.97	-0.68	-0.46	-0.43	0.03	-0.37	0.22	0.14	0.11

This table displays calculated financial ratios and metrics derived from 10x Genomics' official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	105.83%	68.06%	21.53%	64.13%	5.28%	19.81%	-1.28%	5.25%
EBITDA Growth	0.00%	-673.74%	77.88%	-2,077.72%	95.17%	-444.88%	-64.29%	31.34%	89.45%
EBIT Growth	0.00%	-508.69%	72.29%	-1,632.19%	90.04%	-216.92%	-57.98%	26.16%	69.51%
NOPAT Growth	0.00%	-502.80%	72.40%	-1,647.10%	90.22%	-221.41%	-57.99%	26.67%	68.65%
Net Income Growth	0.00%	-499.54%	72.22%	-1,636.68%	89.27%	-185.11%	-53.67%	28.41%	76.16%
EPS Growth	0.00%	-418.52%	90.48%	-571.25%	90.13%	-175.47%	-49.32%	30.28%	76.97%
Operating Cash Flow Growth	0.00%	-614.17%	145.32%	-729.27%	90.19%	-57.24%	54.78%	143.85%	1,941.57%
Free Cash Flow Firm Growth	0.00%	0.00%	9.49%	-587.96%	49.22%	-26.52%	36.94%	39.03%	101.12%
Invested Capital Growth	0.00%	0.00%	311.05%	129.76%	288.94%	62.87%	-5.57%	-10.11%	-13.83%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	14.10%	6.82%	2.52%	4.70%	-3.01%	0.16%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-343.69%	94.08%	-4.90%	-15.12%	-1.55%	66.37%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-302.75%	88.09%	-4.65%	-13.89%	-0.60%	33.59%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-302.70%	88.28%	-4.52%	-13.76%	2.68%	33.19%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-304.14%	87.21%	0.74%	-14.21%	-0.04%	42.95%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-571.25%	88.09%	2.01%	-14.74%	1.30%	43.55%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	250.08%	-168.93%	86.42%	19.07%	44.19%	-82.99%	53.69%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	59.86%	-11.02%	27.71%	-31.01%	102.66%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	1,973.47%	14.69%	15.56%	-9.14%	-2.44%	-9.94%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	85.14%	80.41%	75.18%	80.44%	84.89%	76.69%	66.15%	67.86%	69.05%
EBITDA Margin	-19.39%	-72.89%	-9.59%	-171.92%	-5.06%	-26.17%	-35.88%	-24.96%	-2.51%
Operating Margin	-25.85%	-75.70%	-12.43%	-178.74%	-10.65%	-32.52%	-42.88%	-31.85%	-9.49%
EBIT Margin	-25.66%	-75.87%	-12.51%	-178.29%	-10.82%	-32.56%	-42.93%	-32.11%	-9.33%
Profit (Net Income) Margin	-26.39%	-76.88%	-12.71%	-181.61%	-11.87%	-32.15%	-41.23%	-29.90%	-6.77%
Tax Burden Percent	100.11%	100.08%	100.70%	101.54%	108.39%	102.49%	102.55%	102.77%	109.11%
Interest Burden Percent	102.76%	101.25%	100.89%	100.31%	101.24%	96.33%	93.65%	90.60%	66.56%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-317.31%	-884.57%	-25.40%	-39.04%	-51.20%	-40.71%	-14.48%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-312.73%	-853.15%	-21.99%	-29.55%	-34.31%	-28.84%	-14.29%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	303.21%	790.93%	17.92%	18.59%	18.22%	15.54%	8.70%
Return on Equity (ROE)	0.00%	-483.66%	-14.10%	-93.64%	-7.48%	-20.45%	-32.98%	-25.17%	-5.78%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-230.86%	-963.27%	-143.59%	-86.88%	-45.47%	-30.06%	0.38%
Operating Return on Assets (OROA)	0.00%	-89.30%	-8.42%	-69.41%	-5.45%	-16.42%	-26.64%	-20.82%	-6.12%
Return on Assets (ROA)	0.00%	-90.49%	-8.56%	-70.70%	-5.98%	-16.21%	-25.59%	-19.39%	-4.44%
Return on Common Equity (ROCE)	0.00%	4,574.93%	-6.36%	-93.64%	-7.48%	-20.45%	-32.98%	-25.17%	-5.78%
Return on Equity Simple (ROE_SIMPLE)	0.00%	51.13%	-7.44%	-73.43%	-7.12%	-20.60%	-34.42%	-25.72%	0.00%
Net Operating Profit after Tax (NOPAT)	-13	-78	-21	-374	-37	-118	-186	-136	-43
NOPAT Margin	-18.09%	-52.99%	-8.70%	-125.11%	-7.46%	-22.77%	-30.02%	-22.30%	-6.64%
Net Nonoperating Expense Percent (NNEP)	0.00%	-197.44%	-4.58%	-31.42%	-3.41%	-9.49%	-16.89%	-11.87%	-0.19%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-14.59%	-25.06%	-19.18%	-5.36%
Cost of Revenue to Revenue	14.86%	19.59%	24.82%	19.56%	15.11%	23.31%	33.85%	32.14%	30.95%
SG&A Expenses to Revenue	65.75%	60.10%	53.21%	67.70%	52.51%	57.76%	55.49%	56.38%	49.18%
R&D to Revenue	45.25%	75.11%	33.79%	191.04%	43.17%	51.45%	53.55%	43.34%	37.12%
Operating Expenses to Revenue	110.99%	156.11%	87.61%	259.17%	95.55%	109.21%	109.04%	99.71%	78.54%
Earnings before Interest and Taxes (EBIT)	-18	-111	-31	-533	-53	-168	-266	-196	-60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-14	-107	-24	-514	-25	-135	-222	-152	-16
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	17.46	20.62	20.35	5.18	8.93	2.45	2.59
Price to Tangible Book Value (P/TBV)	0.00	0.00	17.46	21.26	21.13	5.36	9.19	2.52	2.83
Price to Revenue (P/Rev)	5.49	2.67	29.82	50.99	33.93	8.08	10.69	2.85	3.21
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	270.66	247.14	70.07	10.02	17.67	4.25	5.65
Enterprise Value to Revenue (EV/Rev)	0.00	4.09	28.22	48.71	32.73	7.24	10.06	2.20	2.40
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	200.38	0.00	0.00	0.00	0.00	201.82	11.32
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,368.88
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	1.28	0.07	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	1.10	0.05	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-1.52	-0.97	-0.93	-0.82	-0.63	-0.53	-0.54	-0.61
Leverage Ratio	0.00	5.35	1.65	1.32	1.25	1.26	1.29	1.30	1.30
Compound Leverage Factor	0.00	5.41	1.66	1.33	1.27	1.22	1.21	1.18	0.87
Debt to Total Capital	0.00%	56.06%	6.61%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	7.91%	2.20%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	48.15%	4.41%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	459.53%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-415.60%	93.39%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	-0.28	-1.26	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.33	16.72	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	-0.24	-0.84	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-0.38	-1.39	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.46	18.43	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	-0.33	-0.93	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	-1.34	24.13	46.11	49.48	10.36	16.16	3.34	4.06
Noncontrolling Interest Sharing Ratio	0.00%	1,045.90%	54.87%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	3.28	7.63	6.56	6.77	4.85	4.69	4.97	4.46
Quick Ratio	0.00	2.88	7.26	6.05	6.10	4.08	3.96	4.09	3.95
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-65	-59	-407	-207	-262	-165	-101	1.13
Operating Cash Flow to CapEx	-284.85%	-1,215.93%	81.01%	-594.28%	-21.10%	-25.52%	-31.27%	53.77%	2,292.33%
Free Cash Flow to Firm to Interest Expense	0.00	-27.14	-19.22	-242.07	-238.76	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-13.19	-31.72	11.25	-129.55	-24.68	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-17.82	-34.33	-2.64	-151.35	-141.63	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	1.18	0.67	0.39	0.50	0.50	0.62	0.65	0.66
Accounts Receivable Turnover	0.00	5.21	8.00	7.07	7.19	5.45	5.65	6.03	7.52
Inventory Turnover	0.00	3.34	5.12	2.59	1.65	1.70	2.70	2.50	2.85
Fixed Asset Turnover	0.00	13.15	8.20	4.91	4.05	2.25	2.18	2.30	2.68
Accounts Payable Turnover	0.00	3.26	5.59	6.59	6.72	6.18	11.22	13.71	15.52
Days Sales Outstanding (DSO)	0.00	70.07	45.61	51.65	50.77	66.96	64.61	60.56	48.54
Days Inventory Outstanding (DIO)	0.00	109.14	71.29	141.18	221.50	214.65	135.37	145.79	127.92
Days Payable Outstanding (DPO)	0.00	111.97	65.25	55.36	54.34	59.05	32.54	26.63	23.52
Cash Conversion Cycle (CCC)	0.00	67.24	51.65	137.46	217.94	222.56	167.44	179.72	152.94
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	-12	26	59	229	373	352	317	273
Invested Capital Turnover	0.00	-24.09	36.46	7.07	3.41	1.72	1.71	1.83	2.18
Increase / (Decrease) in Invested Capital	0.00	-12	38	33	170	144	-21	-36	-44
Enterprise Value (EV)	0.00	598	6,939	14,557	16,051	3,738	6,226	1,345	1,541
Market Capitalization	390	390	7,333	15,237	16,640	4,171	6,615	1,738	2,064
Book Value per Share	$0.00	($16.43)	$4.37	$6.87	$7.32	$7.04	$6.27	$5.87	$6.29
Tangible Book Value per Share	$0.00	($16.43)	$4.37	$6.66	$7.05	$6.80	$6.09	$5.70	$5.76
Total Capital	0.00	53	450	739	818	806	741	710	796
Total Debt	0.00	30	30	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	25	20	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-35	-394	-680	-588	-433	-389	-393	-523
Capital Expenditures (CapEx)	3.76	6.28	43	37	101	132	49	12	5.94
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	13	3.51	-24	49	71	80	73	7.59
Debt-free Net Working Capital (DFNWC)	0.00	78	428	656	637	504	469	467	531
Net Working Capital (NWC)	0.00	74	418	656	637	504	469	467	531
Net Nonoperating Expense (NNE)	5.90	35	9.85	169	22	48	69	46	0.85
Net Nonoperating Obligations (NNO)	0.00	-35	-394	-680	-588	-433	-389	-393	-523
Total Depreciation and Amortization (D&A)	4.45	4.36	7.17	19	28	33	44	44	44
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	8.87%	1.43%	-8.01%	9.94%	13.84%	12.96%	12.01%	1.18%
Debt-free Net Working Capital to Revenue	0.00%	53.35%	173.93%	219.59%	129.92%	97.61%	75.78%	76.42%	82.60%
Net Working Capital to Revenue	0.00%	50.49%	169.91%	219.59%	129.92%	97.61%	75.78%	76.42%	82.60%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($0.80)	($5.37)	($0.53)	($1.46)	($2.18)	($1.52)	($0.35)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	96.55M	108.75M	110.35M	113.86M	117.17M	120.45M	124.75M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($0.80)	($5.37)	($0.53)	($1.46)	($2.18)	($1.52)	($0.35)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	96.55M	108.75M	110.35M	113.86M	117.17M	120.45M	124.75M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($0.80)	($5.37)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	39.09M	101.15M	112.84M	115.36M	119.17M	122.30M	127.75M
Normalized Net Operating Profit after Tax (NOPAT)	-13	-56	-20	-374	-37	-118	-186	-136	-43
Normalized NOPAT Margin	-18.09%	-38.36%	-8.28%	-125.11%	-7.55%	-22.77%	-30.02%	-22.30%	-6.64%
Pre Tax Income Margin	-26.36%	-76.82%	-12.62%	-178.85%	-10.95%	-31.36%	-40.21%	-29.09%	-6.21%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-22.49	-46.08	-9.99	-316.77	-61.26	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-15.86	-32.19	-6.95	-222.29	-42.24	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-27.12	-48.69	-23.87	-338.57	-178.21	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-20.49	-34.79	-20.83	-244.09	-159.19	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.43%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from 10x Genomics' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	127,752,254.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	127,752,254.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-0.11
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	17.22%	17.76%	5.01%	4.28%	-1.30%	-10.30%	9.84%	12.94%	-1.75%	0.61%	-2.61%
EBITDA Growth	-150.13%	-170.25%	-13.71%	41.69%	66.14%	-5.87%	46.36%	237.18%	26.18%	76.41%	78.26%
EBIT Growth	-128.97%	-121.80%	-16.88%	35.57%	58.97%	-2.30%	40.53%	178.31%	15.23%	58.24%	51.98%
NOPAT Growth	-137.01%	-138.95%	-18.29%	34.13%	56.24%	9.69%	36.05%	196.26%	22.28%	60.79%	56.66%
Net Income Growth	-121.85%	-184.36%	-18.13%	39.28%	61.55%	-0.16%	42.69%	191.14%	23.16%	66.85%	60.80%
EPS Growth	-113.51%	-200.00%	-13.64%	39.62%	62.03%	4.76%	44.00%	187.50%	26.67%	67.50%	64.29%
Operating Cash Flow Growth	-164.58%	87.70%	-281.21%	165.04%	185.52%	-126.20%	318.45%	136.23%	99.69%	704.28%	-23.96%
Free Cash Flow Firm Growth	13.15%	88.86%	94.38%	116.86%	126.00%	104.08%	566.16%	69.16%	-102.81%	4,035.63%	-116.25%
Invested Capital Growth	20.10%	-5.57%	-9.06%	-14.10%	-16.29%	-10.11%	-19.32%	-5.22%	-6.66%	-13.83%	-1.97%
Revenue Q/Q Growth	4.65%	19.74%	-23.36%	8.58%	-0.95%	8.81%	-6.14%	11.64%	-13.83%	11.43%	-9.15%
EBITDA Q/Q Growth	-59.71%	53.30%	-29.16%	39.48%	7.24%	-46.01%	34.57%	254.80%	-149.92%	52.80%	40.40%
EBIT Q/Q Growth	-48.07%	46.66%	-22.08%	33.17%	5.71%	-32.99%	29.03%	188.00%	-202.07%	33.89%	19.13%
NOPAT Q/Q Growth	-49.62%	41.78%	-11.43%	32.13%	0.60%	-20.14%	21.09%	202.16%	-180.25%	39.39%	12.77%
Net Income Q/Q Growth	-48.98%	47.36%	-22.46%	36.78%	5.66%	-37.13%	29.92%	200.52%	-179.54%	40.84%	17.12%
EPS Q/Q Growth	-49.06%	46.84%	-19.05%	36.00%	6.25%	-33.33%	30.00%	200.00%	-178.57%	40.91%	23.08%
Operating Cash Flow Q/Q Growth	-119.54%	201.79%	-161.05%	147.67%	188.70%	-131.18%	609.05%	-48.45%	144.04%	-5.64%	-35.94%
Free Cash Flow Firm Q/Q Growth	18.72%	86.40%	52.54%	421.41%	25.30%	-97.86%	5,320.67%	16.63%	-102.08%	3,237.89%	-121.30%
Invested Capital Q/Q Growth	-3.15%	-9.14%	-1.51%	-0.88%	-5.62%	-2.44%	-11.60%	16.44%	-7.05%	-9.94%	0.57%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	62.18%	62.93%	65.89%	68.07%	70.16%	67.24%	68.08%	72.34%	67.32%	68.09%	70.39%
EBITDA Margin	-55.08%	-21.48%	-36.20%	-20.18%	-18.90%	-25.36%	-17.68%	24.51%	-14.20%	-6.01%	-3.95%
Operating Margin	-61.70%	-30.00%	-43.61%	-27.26%	-27.36%	-30.20%	-25.39%	17.42%	-21.64%	-11.77%	-11.30%
EBIT Margin	-62.51%	-27.84%	-44.35%	-27.30%	-25.98%	-31.76%	-24.01%	18.93%	-22.42%	-13.30%	-11.84%
Profit (Net Income) Margin	-60.52%	-26.61%	-42.52%	-24.75%	-23.58%	-29.71%	-22.18%	19.97%	-18.44%	-9.79%	-8.93%
Tax Burden Percent	101.35%	105.05%	103.71%	102.21%	103.82%	101.34%	102.54%	93.35%	97.40%	106.97%	104.85%
Interest Burden Percent	95.52%	90.96%	92.43%	88.72%	87.39%	92.32%	90.09%	113.04%	84.43%	68.79%	71.93%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	6.65%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-71.83%	-35.82%	-52.41%	-32.39%	-33.85%	-38.60%	-35.42%	31.29%	-30.98%	-17.96%	-18.23%
ROIC Less NNEP Spread (ROIC-NNEP)	-65.25%	-33.30%	-48.15%	-30.14%	-32.07%	-34.98%	-33.71%	29.74%	-29.86%	-17.40%	-17.91%
Return on Net Nonoperating Assets (RNNOA)	34.76%	17.68%	25.09%	15.36%	16.51%	18.85%	18.88%	-16.43%	17.43%	10.59%	11.38%
Return on Equity (ROE)	-37.06%	-18.13%	-27.33%	-17.03%	-17.34%	-19.75%	-16.53%	14.86%	-13.54%	-7.37%	-6.85%
Cash Return on Invested Capital (CROIC)	-64.21%	-45.47%	-43.32%	-32.46%	-21.55%	-30.06%	-17.11%	-15.65%	-13.47%	0.38%	-7.78%
Operating Return on Assets (OROA)	-37.99%	-17.28%	-28.64%	-17.97%	-17.35%	-20.59%	-16.43%	12.78%	-14.64%	-8.73%	-7.88%
Return on Assets (ROA)	-36.78%	-16.51%	-27.46%	-16.29%	-15.74%	-19.27%	-15.17%	13.48%	-12.04%	-6.42%	-5.94%
Return on Common Equity (ROCE)	-37.06%	-18.13%	-27.33%	-17.03%	-17.34%	-19.75%	-16.53%	14.86%	-13.54%	-7.37%	-6.85%
Return on Equity Simple (ROE_SIMPLE)	-29.97%	0.00%	-36.77%	-33.12%	-25.26%	0.00%	-22.21%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-66	-39	-43	-29	-29	-35	-28	28	-23	-14	-12
NOPAT Margin	-43.19%	-21.00%	-30.53%	-19.08%	-19.15%	-21.14%	-17.77%	16.27%	-15.15%	-8.24%	-7.91%
Net Nonoperating Expense Percent (NNEP)	-6.57%	-2.51%	-4.26%	-2.25%	-1.78%	-3.62%	-1.71%	1.55%	-1.11%	-0.56%	-0.32%
Return On Investment Capital (ROIC_SIMPLE)	-	-5.21%	-5.99%	-	-	-4.91%	-3.89%	3.64%	-2.87%	-1.72%	-1.47%
Cost of Revenue to Revenue	37.82%	37.07%	34.11%	31.93%	29.84%	32.76%	31.92%	27.66%	32.68%	31.91%	29.61%
SG&A Expenses to Revenue	53.64%	46.81%	60.83%	54.24%	53.88%	56.86%	57.93%	43.05%	50.57%	46.15%	44.00%
R&D to Revenue	70.23%	46.12%	48.68%	41.09%	43.63%	40.58%	41.48%	35.41%	38.38%	33.71%	37.69%
Operating Expenses to Revenue	123.87%	92.93%	109.51%	95.33%	97.51%	97.44%	93.47%	54.92%	88.96%	79.86%	81.69%
Earnings before Interest and Taxes (EBIT)	-96	-51	-63	-42	-39	-52	-37	33	-33	-22	-18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-85	-40	-51	-31	-29	-42	-27	42	-21	-9.99	-5.95
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.50	8.93	6.17	3.22	3.76	2.45	1.51	1.84	1.85	2.59	3.33
Price to Tangible Book Value (P/TBV)	6.74	9.19	6.35	3.31	3.87	2.52	1.55	1.89	2.03	2.83	3.62
Price to Revenue (P/Rev)	8.20	10.69	7.09	3.69	4.32	2.85	1.71	2.21	2.27	3.21	4.25
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	11.57	17.67	11.71	5.66	7.15	4.25	2.29	3.00	3.21	5.65	7.91
Enterprise Value to Revenue (EV/Rev)	7.59	10.06	6.50	3.08	3.69	2.20	1.03	1.52	1.52	2.40	3.40
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	410.80
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	59.29	201.82	11.29	14.62	10.99	11.32	17.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,368.88	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.53	-0.53	-0.52	-0.51	-0.51	-0.54	-0.56	-0.55	-0.58	-0.61	-0.64
Leverage Ratio	1.28	1.29	1.27	1.26	1.29	1.30	1.28	1.28	1.30	1.30	1.26
Compound Leverage Factor	1.22	1.17	1.18	1.12	1.12	1.20	1.15	1.44	1.10	0.90	0.91
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	13.34	16.90	12.05	5.85	6.61	3.85	2.12	3.48	2.68	4.18	7.21
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.37	4.69	5.22	5.22	4.90	4.97	5.37	5.84	4.48	4.46	5.90
Quick Ratio	4.40	3.96	4.26	4.25	3.97	4.09	4.44	5.05	3.93	3.95	5.25
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-131	-18	-8.47	27	34	0.73	40	46	-0.96	30	-6.42
Operating Cash Flow to CapEx	-166.08%	746.61%	-540.38%	260.46%	556.47%	-248.45%	1,814.63%	1,122.18%	6,290.25%	2,294.71%	1,635.57%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-8,473.60	0.00	0.00	0.00	0.00	15,356.89	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	-15,725.00	0.00	0.00	0.00	0.00	5,902.67	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-18,635.00	0.00	0.00	0.00	0.00	5,376.67	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.61	0.62	0.65	0.66	0.67	0.65	0.68	0.68	0.65	0.66	0.67
Accounts Receivable Turnover	6.31	5.65	7.39	7.06	6.72	6.03	8.68	6.13	7.13	7.52	11.75
Inventory Turnover	2.23	2.70	2.68	2.60	2.41	2.50	2.50	2.50	2.56	2.85	3.03
Fixed Asset Turnover	2.18	2.18	2.23	2.30	2.32	2.30	2.42	2.56	2.61	2.68	2.74
Accounts Payable Turnover	8.81	11.22	8.95	10.06	9.34	13.71	13.05	10.57	9.03	15.52	14.13
Days Sales Outstanding (DSO)	57.87	64.61	49.38	51.67	54.30	60.56	42.03	59.54	51.22	48.54	31.05
Days Inventory Outstanding (DIO)	163.54	135.37	136.29	140.55	151.74	145.79	145.80	145.97	142.34	127.92	120.49
Days Payable Outstanding (DPO)	41.44	32.54	40.79	36.27	39.07	26.63	27.96	34.52	40.40	23.52	25.84
Cash Conversion Cycle (CCC)	179.97	167.44	144.88	155.95	166.98	179.72	159.86	170.99	153.16	152.94	125.70
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	388	352	347	344	325	317	280	326	303	273	274
Invested Capital Turnover	1.66	1.71	1.72	1.70	1.77	1.83	1.99	1.92	2.05	2.18	2.30
Increase / (Decrease) in Invested Capital	65	-21	-35	-56	-63	-36	-67	-18	-22	-44	-5.51
Enterprise Value (EV)	4,486	6,226	4,065	1,948	2,323	1,345	641	979	973	1,541	2,172
Market Capitalization	4,844	6,615	4,436	2,328	2,721	1,738	1,068	1,426	1,455	2,064	2,712
Book Value per Share	$6.35	$6.27	$6.02	$6.05	$6.00	$5.87	$5.78	$6.28	$6.31	$6.29	$6.37
Tangible Book Value per Share	$6.12	$6.09	$5.85	$5.87	$5.83	$5.70	$5.62	$6.12	$5.75	$5.76	$5.87
Total Capital	745	741	719	724	723	710	707	773	785	796	814
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-357	-389	-372	-380	-398	-393	-427	-447	-482	-523	-540
Capital Expenditures (CapEx)	15	3.45	2.91	2.88	3.89	2.72	1.89	1.58	0.69	1.78	1.60
Debt-free, Cash-free Net Working Capital (DFCFNWC)	100	80	87	88	74	73	45	96	30	7.59	16
Debt-free Net Working Capital (DFNWC)	458	469	458	468	473	467	472	543	513	531	556
Net Working Capital (NWC)	458	469	458	468	473	467	472	543	513	531	556
Net Nonoperating Expense (NNE)	27	10	17	8.68	6.71	14	6.83	-6.41	4.90	2.57	1.54
Net Nonoperating Obligations (NNO)	-357	-389	-372	-380	-398	-393	-427	-447	-482	-523	-540
Total Depreciation and Amortization (D&A)	11	12	11	11	11	11	9.81	9.65	12	12	12
Debt-free, Cash-free Net Working Capital to Revenue	16.96%	12.96%	13.84%	13.94%	11.83%	12.01%	7.19%	14.92%	4.74%	1.18%	2.55%
Debt-free Net Working Capital to Revenue	77.44%	75.78%	73.29%	74.10%	75.06%	76.42%	75.53%	84.32%	79.85%	82.60%	87.06%
Net Working Capital to Revenue	77.44%	75.78%	73.29%	74.10%	75.06%	76.42%	75.53%	84.32%	79.85%	82.60%	87.06%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.79)	($0.42)	($0.50)	($0.32)	($0.30)	($0.40)	($0.28)	$0.28	($0.22)	($0.13)	($0.10)
Adjusted Weighted Average Basic Shares Outstanding	117.73M	117.17M	119.39M	120.07M	120.73M	120.45M	122.61M	123.76M	125.50M	124.75M	128.29M
Adjusted Diluted Earnings per Share	($0.79)	($0.42)	($0.50)	($0.32)	($0.30)	($0.40)	($0.28)	$0.28	($0.22)	($0.13)	($0.10)
Adjusted Weighted Average Diluted Shares Outstanding	117.73M	117.17M	119.39M	120.07M	120.73M	120.45M	122.61M	124.51M	125.50M	124.75M	128.29M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	118.21M	119.17M	119.71M	120.49M	121.05M	122.30M	123.13M	124.49M	126.55M	127.75M	126.96M
Normalized Net Operating Profit after Tax (NOPAT)	-66	-39	-43	-29	-29	-35	-28	28	-23	-14	-12
Normalized NOPAT Margin	-43.19%	-21.00%	-30.53%	-19.08%	-19.15%	-21.14%	-17.77%	16.27%	-15.15%	-8.24%	-7.91%
Pre Tax Income Margin	-59.71%	-25.33%	-40.99%	-24.22%	-22.71%	-29.32%	-21.63%	21.40%	-18.93%	-9.15%	-8.52%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-62,538.00	0.00	0.00	0.00	0.00	10,909.67	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	-43,048.60	0.00	0.00	0.00	0.00	9,374.56	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	-65,448.00	0.00	0.00	0.00	0.00	10,383.67	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	-45,958.60	0.00	0.00	0.00	0.00	8,848.56	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the top takeaways from 10x Genomics (TXG) quarterly statements over the last four years, focused on revenue, profitability, cash flow, and balance-sheet trends. Items are ordered with positives first, then neutral, then negatives.

Operating cash flow from continuing operations turned solidly positive in Q4 2025 at about $40.8 million, with healthy cash generation sustained into Q3 and Q2 2025.
Cash and cash equivalents rose through 2025, with about $432.5 million in place by Q3 2025 (up from roughly $377.1 million at the start of the year), signaling improving liquidity.
Net income was positive in Q2 2025 (+$34.5 million), showing a quarterly path toward profitability before other items.
Gross margins remained robust, generally in the 67%–72% range through 2023–2025, indicating sustained top-line profitability on product sales.
SG&A and R&D spending trended toward cost discipline in 2025, with SG&A running in the mid-40s percent of revenue in several quarters and R&D stabilizing, supporting stronger operating leverage.
Total equity expanded to about $785 million by Q3 2025, strengthening the balance sheet and providing a cushion for ongoing investments.
A sizable asset base remains active, with PPE (plant, property & equipment, net) around the low-to-mid $200s millions (about $232.5 million by Q3 2025), indicating continued platform investment alongside depreciation.
Issuance of common equity occurred in several quarters (e.g., roughly $2.24 million in Q4 2025 and other smaller amounts in prior periods), providing liquidity but implying some dilution for existing shareholders.
Net income has been negative in most quarters in 2025 (e.g., -$16.3 million in Q4 2025 and -$27.5 million in Q3 2025), underscoring ongoing profitability challenges.
Total current liabilities rose through 2025 (about $147 million by Q3 2025), and total liabilities grew, signaling higher funding needs and potential liquidity risk if operating results deteriorate.

05/14/26 10:51 PM ETAI Generated. May Contain Errors.

10x Genomics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, 10x Genomics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

10x Genomics' net income appears to be on an upward trend, with a most recent value of -$43.54 million in 2025, rising from -$18.76 million in 2017. The previous period was -$182.63 million in 2024. See 10x Genomics' forecast for analyst expectations on what's next for the company.

10x Genomics' total operating income in 2025 was -$60.99 million, based on the following breakdown:

Total Gross Profit: $443.88 million
Total Operating Expenses: $504.87 million

Over the last 8 years, 10x Genomics' total revenue changed from $71.09 million in 2017 to $642.82 million in 2025, a change of 804.3%.

10x Genomics' total liabilities were at $245.04 million at the end of 2025, a 17.5% increase from 2024, and a 142.5% increase since 2018.

In the past 7 years, 10x Genomics' cash and equivalents has ranged from $65.08 million in 2018 to $663.60 million in 2020, and is currently $473.97 million as of their latest financial filing in 2025.

Over the last 8 years, 10x Genomics' book value per share changed from 0.00 in 2017 to 6.29 in 2025, a change of 629.2%.

Related Companies

Financial statements for NASDAQ:TXG last updated on 5/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

10x Genomics (TXG) Financials

Financials Breakdown Chart

Key Financial Trends

10x Genomics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

10x Genomics (TXG) Financials

Annual Income Statements for 10x Genomics

Quarterly Income Statements for 10x Genomics

Annual Cash Flow Statements for 10x Genomics

Quarterly Cash Flow Statements for 10x Genomics

Annual Balance Sheets for 10x Genomics

Quarterly Balance Sheets for 10x Genomics

Annual Metrics And Ratios for 10x Genomics

Quarterly Metrics And Ratios for 10x Genomics

Financials Breakdown Chart

Key Financial Trends

10x Genomics Financials - Frequently Asked Questions

When does 10x Genomics' fiscal year end?

How has 10x Genomics' net income changed over the last 8 years?

What is 10x Genomics' operating income?

How has 10x Genomics' revenue changed over the last 8 years?

How much debt does 10x Genomics have?

How much cash does 10x Genomics have?

How has 10x Genomics' book value per share changed over the last 8 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools